PMID- 8409438
OWN - NLM
STAT- MEDLINE
DCOM- 19931117
LR  - 20061115
IS  - 0022-1767 (Print)
IS  - 0022-1767 (Linking)
VI  - 151
IP  - 9
DP  - 1993 Nov 1
TI  - Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- 
      and host-specific alloantigens.
PG  - 4803-10
AB  - The graft-vs-leukemia (GVL) effect and its connection to graft-vs-host disease 
      (GVHD) were studied in F1 hybrid mice after parental bone marrow transplantation. 
      (BALB/c x C57BL/6) F1 mice (F1) were sublethally and lethally irradiated and 
      inoculated with 10(4) BCL1 cells, a murine leukemia of BALB/c (BALB) origin. 
      Subsequently mice were transplanted with F1 (syngeneic), BALB (allogeneic to the 
      host but syngeneic to the tumor), C57BL/6 (B6) (allogeneic to both host and 
      tumor) spleen cells, or spleen cells mixed with syngeneic (F1) bone marrow cells, 
      respectively. Fresh BALB (H-2d) and B6 (H-2b) spleen cells, which induce equally 
      strong GVHD in the F1 recipient against H-2b and H-2d alloantigens, respectively, 
      were assayed for their ability to induce GVL effects on BCL1 (H-2d) cells with 
      and without in vivo administration of human rIL-2. In order to increase the GVL 
      effects, spleen cells were incubated for 4 days with rIL-2 to generate 
      IL-2-activated killer cells. The results of adoptive transfer experiments showed 
      that only immunocompetent B6 cells led to consistent eradication of leukemia. 
      Neither BALB nor syngeneic F1 cells induced curative GVL effects regardless of 
      whether spleen cells were further stimulated with rIL-2 in vitro, in vivo, or 
      both. Our data support the theory that GVL effects are caused by T cell-dependent 
      immune responses of allogeneic T cells and not by MHC-nonrestricted NK or 
      rIL-2-activated NK cells, independently of the GVHD process itself. Hence, 
      recognition and killing of tumor cells is most probably a MHC-restricted T 
      cell-dependent process.
FAU - Cohen, P
AU  - Cohen P
AD  - Department of Bone Marrow Transplantation, Hadassah University Hospital, 
      Jerusalem, Israel.
FAU - Vourka-Karussis, U
AU  - Vourka-Karussis U
FAU - Weiss, L
AU  - Weiss L
FAU - Slavin, S
AU  - Slavin S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (H-2 Antigens)
RN  - 0 (Interleukin-2)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Animals
MH  - Bone Marrow Transplantation
MH  - Graft vs Host Disease/immunology
MH  - H-2 Antigens/*immunology
MH  - *Immunotherapy, Adoptive
MH  - Interleukin-2/*pharmacology
MH  - Killer Cells, Lymphokine-Activated/immunology
MH  - Leukemia, Experimental/*immunology/therapy
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Recombinant Proteins/pharmacology
MH  - T-Lymphocytes/*immunology
MH  - Whole-Body Irradiation
EDAT- 1993/11/01 00:00
MHDA- 1993/11/01 00:01
CRDT- 1993/11/01 00:00
PHST- 1993/11/01 00:00 [pubmed]
PHST- 1993/11/01 00:01 [medline]
PHST- 1993/11/01 00:00 [entrez]
PST - ppublish
SO  - J Immunol. 1993 Nov 1;151(9):4803-10.